Untitled Page

   Clinical Research Support | Departments | Trials | Frequently Asked Questions | Request Trial Information

 

Clinical Trial Listing

2002.354.C - Gastrointestinal Motility Disorder and the effects of Cisapride 
This study seeks to provide an alternative to patients who have failed standard therapy and have no therapeutic options.
 
2003.845.W - Fecal Incontinence and the effects of Medtronic InterStim Therapy 
This study is assessing the safety and effectiveness of stimulating the sacral nerve using the Medtronic InterStim Therapy for patients with fecal incontinence.
 
2008.124.N - Rectal Cancer and the effects of Laparoscopic-Assisted vs Open Resection 
This randomized phase III trial is studying laparoscopic-assisted resection to see how well it works compared with open resection in treating patients with stage IIA, stage IIIA, or stage IIIB rectal cancer.
 
2009.053.B - Chronic Liver Disease and the effects of E5501 
A new, investigational drug, E5501, is being studied as a possible treatment for low platelets counts in subjects with chronic liver disease who are scheduled to undergo elective surgical or diagnostic procedures. The purpose of this study is to evaluate the effects of E5501 on the platelet level in the blood.
 
2009.134.C - Crohn's Disease and the effects of Cimzia 
The purpose of this observational registry is to collect information on the long-term use and safety of Cimzia® as compared to other Crohn’s disease medications prescribed by your doctor in routine clinical practice.
 
2009.148.A - Radical Cystectomy and the effects of Alvimopan on Gastrointestinal Function 
The primary purpose of the study is to demonstrate that the drug alvimopan accelertaes recovery of gastrointestinal function in subjects undergoing radical cystectomy, a surgery to remove the bladder. It will also look at in particular, cardiovascular safety of the drug.
 
2010.037.B - Gastrointestinal Disorders and the effects of Domperidone 
The purpose of this expanded access program is to provide oral domperidone in the United States to patients for the relief of gastrointestinal (GI) symptoms associated with gastrointestinal motility disorders after currently approved treatments have not worked.   
 
2010.061.A - Colon Cancer and the effects of Rosuvastatin 
This randomized phase III trial is studying rosuvastatin to see how well it works compared with placebo in treating patients with stage I or stage II colon cancer that was removed by surgery.
 
2010.084.N - Pancreas and the effects of Erlotinib and Chemoradiation 
This randomized phase III trial is studying gemcitabine hydrochloride and erlotinib hydrochloride to see how well they work compared with gemcitabine hydrochloride alone followed by the same chemotherapy regimen with or without radiation therapy and capecitabine or fluorouracil in treating patients with pancreatic cancer that was removed by surgery.
 
2010.084.N - Pancreatic Cancer and the Effects of Both Erlotinib and Chemoradiation as Adjuvant Treatment After Resection 

This randomized phase III trial is studying gemcitabine hydrochloride and erlotinib hydrochloride to see how well they work compared with gemcitabine hydrochloride alone followed by the same chemotherapy regimen with or without radiation therapy and capecitabine or fluorouracil in treating patients with pancreatic cancer that was removed by surgery. Drugs used in chemotherapy, such as gemcitabine hydrochloride, capecitabine, and fluorouracil, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Erlotinib hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Radiation therapy uses high energy x-rays to kill tumor cells. Giving chemotherapy together with or without erlotinib hydrochloride and/or radiation therapy after surgery may kill any tumor cells that remain after surgery. It is not yet known whether chemotherapy is more effective when given with or without erlotinib hydrochloride and/or radiation therapy in treating pancreatic cancer

 

 

 
2010.096.N - Liver Cancer and the effects of Sorafenib Tosylate and Doxorubicin Hydrochloride 
Sorafenib tosylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. Drugs used in chemotherapy, such as doxorubicin hydrochloride, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. It is not yet known whether giving sorafenib tosylate together with doxorubicin hydrochloride is more effective than sorafenib tosylate alone in treating liver cancer.
 
2010.107.B - Crohn's Disease and the effects of REMICADE (infliximab) 
The purpose of this study is to assess the effects of REMICADE® (infliximab) in preventing relapse of Crohn’s Disease (CD) after surgical resection.
 
2010.156.N - Colon Cancer and the effects of Celecoxib 
This randomized phase III trial is studying giving oxaliplatin, leucovorin calcium, and fluorouracil together to compare how well they work when given together with or without celecoxib in treating patients with stage III colon cancer previously treated with surgery.
 
2010.184.A - Pancreatic Cancer and the Effects of HyperAcute®-Pancreas Immunotherapy 
The purpose of this study is to assess overall survival after treatment with a regimen of adjuvant therapy (Gemcitabine alone or with 5-FU chemoradiation) with or without HyperAcute®-Pancreas (algenpantucel-L) immunotherapy in subjects who have undergone surgical resection.
 
2011.016.A - Hepatitis C and the Effects of TMC435 vs Placebo 
The purpose of this study is to see how well TMC435 will work on slowing down or stopping the growth of the HCV (Hepatitis C) when given with pegylated interferon and ribavirin.
 
2011.016.A Hepatitis C and the Effects of TMC 435, Peginterferon a-2a/a-2b, and Ribavirin 
The purpose of this study is to see how well TMC435 will work on slowing down or stopping the growth of the HCV (Hepatitis C) when given with pegylated interferon and ribavirin.
 
2012.093.N - Esophageal Cancer and the Effects of Traztuxumab to treatment for HER2-Overexpressing Tmors 
This randomized phase III trial is studying how well giving radiation therapy, paclitaxel, and carboplatin together with or without trastuzumab works in treating patients with esophageal cancer.
 
2012.117.N - Hepatocellular Cancer and the Effects of Chemoembolization With or Without Sorafenib 
This randomized phase III trial is studying chemoembolization and sorafenib tosylate to see how well they work compared with chemoembolization alone in treating patients with liver cancer that cannot be removed by surgery
 
2012.118.N - Rectal Cancer and The Effects of Chemotherapy Alone or Chemotherapy Plus Radiation Therapy in Treating Patients Undergoing Surgery 

Drugs used in chemotherapy, such as oxaliplatin, leucovorin calcium, fluorouracil, and capecitabine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Radiation therapy uses high-energy x-rays to kill tumor cells. It is not yet known whether chemotherapy alone is more effective then chemotherapy plus radiation therapy in treating rectal cancer. This randomized phase II/III trial studies how well chemotherapy alone compared to chemotherapy plus radiation therapy works in treating patients with rectal cancer undergoing surgery

 

 
2012.174.A - Ovarian, Primary Peritoneeal, or Fallopian Tube Cancer and the Effects of Chemotherapy Toxicity On Quality of Life 
This trial studies the chemotherapy toxicity on quality of life in older patients with stage I, stage II, stage III, or stage IV ovarian epithelial, primary peritoneal cavity, or fallopian tube cancer
 
2012.200.B - Metastatic Pancreatic Cancer and the Effects of Selumetinib and Akt Inhibitor MK2206 or mFOLFOX Therapy Comprising Oxaliplatin and Fluorouracil 

This randomized phase II trial studies how well selumetinib and Akt inhibitor MK2206 work compared to mFOLFOX therapy in treating patients with metastatic pancreatic cancer previously treated with chemotherapy. Selumetinib and Akt inhibitor MK2206 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as oxaliplatin, and fluorouracil, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. It is not yet know whether selumetinib and Akt inhibitor MK2206 are more effective than oxaliplatin and fluorouracil in treating patients with metastatic pancreatic cancer.


 
2012.214.N - Hepatoblastoma and the Effects of Combination Chemotherapy 
This phase III trial is studying the side effects of giving doxorubicin hydrochloride together with combination chemotherapy and to compare different chemotherapy regimens to see how well they work in treating young patients with newly diagnosed liver cancer.
 
2013.062.C - Pancreatic Cancer and The Effects of Chemotherapy and Radiation Therapy Before Surgery Followed by Gemcitabine 

This pilot clinical trial studies combination chemotherapy and radiation therapy before surgery followed by gemcitabine hydrochloride in treating patients with pancreatic cancer when the tumor is borderline for removal. Drugs used in chemotherapy, such as oxaliplatin, irinotecan hydrochloride, leucovorin calcium, fluorouracil, and gemcitabine hydrochloride, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Radiation therapy uses high-energy x-rays to kill tumor cells. Giving combination chemotherapy together with radiation therapy before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be removed. Giving chemotherapy after surgery may kill any tumor cells that remain after surgery

 

 
2013.146.B - Carcinoid Tumors and the Effects of Pazopanib vs. Placebo 

This randomized phase II trial studies how well pazopanib hydrochloride works in treating patients with progressive carcinoid tumors. Pazopanib hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.


 
2013.147.B - Pancreatic Neuroendocrine tumor and the effects of Temozolomide With or Without Capecitabine 

This randomized phase II trial studies how well giving temozolomide with or without capecitabine works in treating patients with advanced pancreatic neuroendocrine tumors. Drugs used in chemotherapy, such as temozolomide and capecitabine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. It is not yet known whether temozolomide is more effective with or without capecitabine in treating patients with advanced pancreatic neuroendocrine tumors.


 
2013.175.B - Advanced or Metastatic Esophageal, Gastric, or Gastroesophageal Junction Cancer and the Effects of Combination Chemo 

 Drugs used in chemotherapy, such as oxaliplatin, leucovorin calcium, fluorouracil, irinotecan hydrochloride, and docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Combining more than one drug may kill more tumor cells. It is not yet known which regimen of combination chemotherapy is more effective in treating tumor cells. This randomized phase II trial studies how well oxaliplatin, leucovorin calcium, and fluorouracil work compared to irinotecan hydrochloride and docetaxel in treating patients with esophageal cancer, gastric cancer, or gastroesophageal junction cancer

 

 

Search by Keyword

Request Trial Information

NIH Logo

Ochsner Specialty Research Locations

Browse by Subject

Browse by Location

menu top
Left Menu Home Small
Left Menu CTU Small
Left Menu Leadership Small
Left Menu Give Small
Left Menu Contact Small
Left Menu UQ
menu bottom
Untitled Page